Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled pilot study of the efficacy and safety
of baloxavir in combination with oseltamivir (standard of care) for the treatment of
influenza in allogeneic stem cell transplant patients. Although there are no data about this
treatment option currently available, the investigator hypothesizes that combination therapy
may be more effective in clearing influenza virus infection and decreasing the rate of
emergence of resistant influenza in immunocompromised human hosts.